No black box warning on record for Hernexeos

As of the latest FDA labeling reviewed, Hernexeos (ZONGERTINIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Hernexeos medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Monitor liver function tests including ALT, AST, and total bilirubin at baseline prior to administration, every 2 weeks during the first 12 weeks, and then monthly thereafter as clinically indicated, with more frequent testing in patients who develop transaminase elevations. Interrupt, reduce the dose, or permanently discontinue HERNEXEOS based on severi

No black box warning on record for Hernexeos

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Monitor liver function tests including ALT, AST, and total bilirubin at baseline prior to administration, every 2 weeks during the first 12 weeks, and then monthly thereafter as clinically indicated, with more frequent testing in patients who develop transaminase elevations. Interrupt, reduce the dose, or permanently discontinue HERNEXEOS based on severi

Hernexeos Black Box Warning

No black box warning on record for Hernexeos

Other warnings & precautions

Hernexeos Black Box Warning

No black box warning on record for Hernexeos

Other warnings & precautions